Directorio

We are doing this study to find out if an experimental drug called ruxolitinib is a safe and effection option for preventing graft-versus-host disease when it is given in combination with the drugs tacrolimus and methotrexate before and after a peripheral blood stem cell transplant. We want to know if this study drug combination works better than the standard post-transplant treatment of cyclophosphamide, tacrolimus, and mycophenolate mofetil.

We are doing this study to find out if patients with SAA who have not received previous treatment for this diagnosis can be treated safely and effectively with transplant as their first therapy.

We are doing this study to see if a pair of experimental drugs called botensilimab and balstilimab are safe and effective options for colorectal cancer.

We are doing this study to try and find a way to detect breast cancer earlier or before it recurs.

We are doing this study to determine if long-term treatment with camizestrant after surgery is a safe and effective option for treating patients with early-stage ER+/HER2- breast cancer. We want to compare the outcomes of using camizestrant to current standard of care treatments (endocrine therapy).

We are doing this study to find out if an experimental drug called AS 1763 (the study drug) is a safe and effective option patients with B-cell cancers. We also want to know what the maximum, safe dose of the study drug is.

We are doing this study to find the safest and most effective dose of an experimental drug called Cilta-cel (the study drug) in patients with multiple myeloma (MM).

We are doing this study to find out if an experimental drug called CAP-100 (study drug) is a safe and effective treatment for people who have CLL or SLL that is not responding to standard treatments. We also want to know what dose of this study drug works best.